Patient derived xenograft (PDX) models are an innovative tool to use human cancer tissue to establish a mouse model and study cancer biology and drug testing. PDX models help retain the genetic and molecular characteristics of the original patient's tumor and demonstrate clinical relevance by recapitulating responses to therapy similarly to patients in clinical trials. They provide a renewable pre-clinical model system to understand cancer development and progression. PDX models help identify new therapeutic strategies and biomarkers for cancer treatment.

The Global Patient Derived Xenograft Model Market is estimated to be valued at US$ 105.4 Mn in 2024 and is expected to exhibit a CAGR of 18.% over the forecast period 2024 To 2031.

Key Takeaways

Key players operating in the Patient Derived Xenograft Model are Aksa Akrilik Kimya Sanayii A.S.(Aksa), Dralon, Aditya Birla Group, Jilin Chemical Fibre Company, Taekwang Industrial Co., LTD, Exlan Japan Co., Ltd., Kaneka Corporation, Indian Acrylics Limited, Pasupati Acrylon Ltd., and Vardhman Acrylics Ltd. These players are focusing on developing advanced PDX models through collaborations and acquisitions.

The key opportunities in the Patient Derived Xenograft Model Market Demand are increasing R&D investment by pharmaceutical companies in personalized cancer medicine and growing demand for cancer research. Furthermore, the rising adoption of PDX models over cell lines for translational research will support market growth over the forecast period.

Technological advancements in areas of tissue engineering, organ-on-chip technologies and humanized mouse techniques are further enhancing predictive power of PDX models. Developments in genome sequencing techniques are improving molecular characterization of PDX models.

Get More Insights on- Patient Derived Xenograft Model Market